Patents
Literature
1 results about "Norepinephrine transporter" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The norepinephrine transporter (NET), also known as solute carrier family 6 member 2 (SLC6A2), is a protein that in humans is encoded by the SLC6A2 gene. NET is a monoamine transporter and is responsible for the sodium-chloride (Na⁺/Cl⁻)-dependent reuptake of extracellular norepinephrine (NE), which is also known as noradrenaline. NET can also reuptake extracellular dopamine (DA). The reuptake of these two neurotransmitters is essential in regulating concentrations in the synaptic cleft. NETs, along with the other monoamine transporters, are the targets of many antidepressants and recreational drugs. In addition, an overabundance of NET is associated with ADHD. There is evidence that single-nucleotide polymorphisms in the NET gene (SLC6A2) may be an underlying factor in some of these disorders.
Prodrugs targeting norepinephrine transporters for cancer therapy
PendingCN122138830APharmaceutical non-active ingredientsHeterocyclic compound active ingredientsCamptothecinNeuroblastoma
Macromolecular prodrugs are provided in which 7-hydroxymethyl camptothecin (CPT-MeOH) is covalently bonded to a polymer through an ester linkage that is unstable under physiological conditions. The CPT-MeOH can be functionalized with a norepinephrine transporter (NET) ligand. Methods of treating cancer, particularly neuroblastoma, with the macromolecular prodrugs are also provided.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA